Evaxion Biotech Expands Board of Directors with Leading Expert in Infectious Diseases .
Steven Projan, Ph.D., an accomplished veteran in the industry with a very successful track record of drug discovery and development, will help to guide Evaxion’s efforts to become the world leader in immuno-informatics, translating big data to design and develop patient-specific vaccines using AI and algorithms.
“We are excited to add Steve to our board and look forward to the contribution he will make in the years ahead,” said Lars Wegner, chief executive officer at Evaxion Biotech. “His expertise and insight will be invaluable assets to Evaxion as we advance our infectious disease and cancer programs through the clinic.”
Steve is the Sr V.P. R&D and Head of Infectious Disease & Vaccines at MedImmune. Prior to working at MedImmune, Steve served as V.P., Global and Head of Infectious Disease at Novartis and V.P. and Head of Biological Technologies at Wyeth. Steve is an expert in infectious diseases, having worked many years with both basic and applied research, successfully led four programs resulting in the approval of novel anti-infective drugs with other in various stages of development and produced more than 110 peer-reviewed publications.